Delving into the Latest Updates on GFS202A with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

GFS-202A

Target

GDF15 x IL-6

Action

inhibitors

Mechanism

GDF15 inhibitors(Growth/differentiation factor 15 inhibitors), IL-6 inhibitors(Interleukin-6 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication

Pancreatic adenocarcinomaAdvanced Malignant Solid NeoplasmCachexia+ [1]

Inactive Indication-

Originator Organization

Genfleet Therapeutics (Shanghai), Inc.

Active Organization

Genfleet Therapeutics (Shanghai), Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

A Phase II, Multicenter, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of GFH375 in Combination With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy. The purpose of this study is to evaluate the anti-tumor efficacy of GFH375 plus GFH276 versus GFH375 monotherapy, and to assess the impact of GFH375 plus GFS202A versus GFH375 monotherapy on patient body weight.

Start Date31 Aug 2026

Sponsor / Collaborator

Genfleet Therapeutics (Shanghai), Inc.

NCT06898255

/ RecruitingPhase 1

An Open-label, Multi-center, Phase I Study to Evaluate the Safety/Tolerability and Pharmacokinetics of GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

An open-label, multi-center, phase I study to evaluate the safety/tolerability and pharmacokinetics of GFS202A in advanced solid tumor patients with pre-cachexia or cachexia. The primary objective is to assess the safety/tolerability of GFS202A, determine its maximum tolerated dose (MTD), and recommend a dose range for future studies.
Enroll participants with cancer cachexia or precachexia to receive GFS202A monotherapy. During the study period, participants will undergo assessments for safety and preliminary efficacy according to the visit schedule. Pharmacokinetic, anti-drug antibody (ADA), and pharmacodynamic (PD) /biomarker samples will be collected.

Start Date24 Apr 2025

Sponsor / Collaborator

Genfleet Therapeutics (Shanghai), Inc.

100 Clinical Results associated with GFS202A

Login to view more data

100 Translational Medicine associated with GFS202A

Login to view more data

100 Patents (Medical) associated with GFS202A

Login to view more data

100 Deals associated with GFS202A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic adenocarcinoma	Phase 2	China	Genfleet Therapeutics (Shanghai), Inc.	31 Aug 2026
Advanced Malignant Solid Neoplasm	Phase 1	China	Genfleet Therapeutics (Shanghai), Inc.	24 Apr 2025
Cachexia	Phase 1	China	Genfleet Therapeutics (Shanghai), Inc.	16 Apr 2025
KRAS G12D mutation Solid Tumors	IND Approval	China	Genfleet Therapeutics (Shanghai), Inc.	15 Jul 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data